Stilla Technologies Partners with Source BioScience to Advance Genomics in the UK and Ireland

Quell Therapeutics and AstraZeneca Advance CAR-Treg Therapy for Type 1 Diabetes

AbbVie’s ELAHERE® Approved in the EU for Platinum-Resistant Ovarian Cancer

AstraZeneca’s Tagrisso Recommended for Approval in EU for Unresectable EGFR-Mutated NSCLC

Foundation Medicine Receives FDA Approval for FoundationOne®Liquid CDx as a Companion Diagnostic for TEPMETKO® in NSCLC

Exact Sciences Partners with Carlos Ponce to Boost Colorectal Cancer Awareness in the Hispanic Community

Merck Receives Positive CHMP Opinion for KEYTRUDA® in Combination Therapy for First-Line Treatment of Non-Epithelioid Mesothelioma

Australia Launches Genomics Australia to Lead Advances in Genomic Medicine

Sidra Medicine Unveils Masterclasses Ahead of PMFG 2024 Summit

FDA Approves Revuforj® as First Menin Inhibitor for Acute Leukemia with KMT2A Translocation

CHMP Recommends Approval of Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H/dMMR Metastatic Colorectal Cancer

ADDF Invests $1.18M to Standardize p-tau217 Blood Tests for Alzheimer’s Diagnosis

GSK Reports Positive Interim Results for DREAMM-7 Trial of Blenrep in Multiple Myeloma

Molbio Diagnostics Invests $30 Million in OptraSCAN to Revolutionize Digital Pathology

BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

Home
/
update
/
details

Pathkind Diagnostics and Sebia Partner to Transform Autoimmune Disease Diagnostics in India

NextEdge Admin

18 Oct 2024

2 min 22 sec

Autoimmune diseases, which impact millions globally, often require complex diagnostic procedures, leading to delayed treatment and poorer patient outcomes. Addressing this challenge, Pathkind Diagnostics, based in Gurugram, has partnered with Sebia to introduce an advanced, user-friendly diagnostic tool aimed at improving patient care.

Through this collaboration, Pathkind will integrate Sebia’s Alegria system into its network, making high-precision autoimmune testing more accessible across India. The Alegria platform employs a monostrip format that simplifies the testing process without compromising accuracy. By reducing the strain on laboratory resources, this solution allows healthcare professionals to provide quicker interventions and improve patient outcomes.

Alegria offers a sample-to-result diagnostic solution for a range of autoimmune conditions, including Rheumatology, Thrombosis, ANCA-associated Vasculitis, Gastroenterology, Thyroid disorders, and Stool testing. Each Monotest strip contains all necessary reagents for a single patient’s analysis and features integrated controls to ensure reliable, high-quality results.

Post-pandemic, India has witnessed a surge in autoimmune disorders, heightening the demand for advanced diagnostic solutions. These conditions are often underdiagnosed or misdiagnosed, leading to treatment delays and worsening health outcomes. With Alegria’s precise and efficient testing capabilities, the partnership aims to bridge this diagnostic gap, offering rapid and reliable results that enable early detection and better disease management.

This initiative not only addresses a pressing public health need but also empowers healthcare providers with the tools to deliver timely and effective patient care, ultimately improving quality of life for those affected by autoimmune disorders.